CASI Pharmaceuticals, Inc (DE)
CASI evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $1.8M
- Lead Asset:
- bi-1206 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CASI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.8M
Cash Runway
—
Lead Asset
bi-1206 (Phase 1)
Next Catalyst
—
Tracking 6 pipeline candidates · 1 FDA decision for CASI Pharmaceuticals, Inc (DE).
Run CASI Pharmaceuticals, Inc (DE) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CASI Pharmaceuticals, Inc (DE) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 0.5%
- Days to cover
- 2.4
- Shares short
- 90,948
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CASI short interestGovernance
Frequently asked questions
What is CASI Pharmaceuticals, Inc (DE)'s lead drug candidate?
CASI Pharmaceuticals, Inc (DE)'s most advanced tracked candidate is bi-1206 (Phase 1) for hematological malignancies and solid tumors.
Who is the CEO of CASI Pharmaceuticals, Inc (DE)?
Crown Bioscience is the chief executive officer of CASI Pharmaceuticals, Inc (DE) (CASI).
Where is CASI Pharmaceuticals, Inc (DE) headquartered?
CASI Pharmaceuticals, Inc (DE) (CASI) is headquartered in Beijing, China.
What therapeutic areas does CASI Pharmaceuticals, Inc (DE) focus on?
CASI Pharmaceuticals, Inc (DE) develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.